Variable screening and model construction for prognosis of elderly patients with lower-grade gliomas based on LASSO-Cox regression: a population-based cohort study DOI Creative Commons
Xiaodong Niu, Chang Tao, Yuekang Zhang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 11, 2024

This study aimed to identify prognostic factors for survival and develop a nomogram predict the probability of elderly patients with lower-grade gliomas (LGGs).

Language: Английский

A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging DOI
Philipp Kickingereder, Philipp Karschnia, Felix Sahm

et al.

Korean Journal of Radiology, Journal Year: 2025, Volume and Issue: 26(3), P. 246 - 246

Published: Jan. 1, 2025

The paradigm of isocitrate dehydrogenase (IDH)-wildtype glioblastoma is rapidly evolving, reflecting clinical, pathological, and imaging advancements. Thus, it remains challenging for radiologists, even those who are dedicated to neuro-oncology imaging, keep pace with this progressing field provide useful updated information clinicians. Based on current knowledge, radiologists can play a significant role in managing patients IDH-wildtype by providing accurate preoperative diagnosis as well postoperative treatment planning including delineation the residual tumor. Through active communication clinicians, extending far beyond confines radiology reading room, impact clinical decision making. This Part 1 review provides an overview about neuropathological understand past, present, upcoming revisions World Health Organization classification. findings that noteworthy while communicating clinicians immediate glioblastomas will be summarized.

Language: Английский

Citations

1
Unraveling the heterogeneity of WHO grade 4 gliomas: insights from clinical, imaging, and molecular characterization DOI Creative Commons
Haihui Jiang, Xijie Wang, Xiaohong Chen

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 3, 2025

Language: Английский

Citations

0
Analysis of clinical, histological, and genomic information of molecular glioblastoma in a Japanese glioma cohort DOI
Ryutaro Makino, Madan Bajagain, Nayuta Higa

et al.

Brain Tumor Pathology, Journal Year: 2025, Volume and Issue: unknown

Published: April 6, 2025

Language: Английский

Citations

0
Multimodal fusion of radio-pathology and proteogenomics identify integrated glioma subtypes with prognostic and therapeutic opportunities DOI Creative Commons
Zaoqu Liu, Yushuai Wu, Hui Xu

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 13, 2025

Integrating multimodal data can uncover causal features hidden in single-modality analyses, offering a comprehensive understanding of disease complexity. This study introduces fusion subtyping (MOFS) framework that integrates radiological, pathological, genomic, transcriptomic, and proteomic from 122 patients with IDH-wildtype adult glioma, identifying three subtypes: MOFS1 (proneural) favorable prognosis, elevated neurodevelopmental activity, abundant neurocyte infiltration; MOFS2 (proliferative) the worst superior proliferative genome instability; MOFS3 (TME-rich) intermediate immune stromal components, sensitive to anti-PD-1 immunotherapy. STRAP emerges as prognostic biomarker potential therapeutic target for MOFS2, associated its phenotype. Stromal infiltration serves crucial indicator, allowing further stratification. Additionally, we develop deep neural network (DNN) classifier based on radiological enhance clinical translatability, providing non-invasive tool predicting MOFS subtypes. Overall, these findings highlight improving classification, accuracy, precision therapy an avenue personalized management.

Language: Английский

Citations

0
Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play DOI Creative Commons
Laveniya Satgunaseelan,

Joanne Sy,

Brindha Shivalingam

et al.

Pathology, Journal Year: 2023, Volume and Issue: 56(2), P. 158 - 169

Published: Dec. 12, 2023

Central nervous system (CNS) tumours were one of the first cancer types to adopt and integrate molecular profiling into routine clinical diagnosis in 2016. The vast majority these biomarkers, used discriminate between tumour types, also offered prognostic information. With advent Cancer Genome Atlas (TCGA) other large genomic datasets, further sub-stratification was possible within leading increased precision CNS grading. This review outlines evolution landscape adult tumours, through prism World Health Organization (WHO) Classifications. We begin our journey pre-molecular era, where high-grade gliomas divided 'primary' 'secondary' glioblastomas. Molecular alterations explaining clinicopathological observations branching points glioma diagnostics, with discovery IDH1/2 mutations 1p/19q codeletion. Subsequently, rigorous characterisation paediatric led unearthing histone H3 as a key event gliomagenesis, which had implications for young patients. Simultaneously, studies investigating biomarkers undertaken. Certain phenotypes found portend unfavourable outcomes, example, MYCN amplification spinal ependymoma. arrival methylation profiling, having revolutionised now promises bring accuracy, has been shown meningiomas. While MGMT promoter hypermethylation remained reliable biomarker response cytotoxic chemotherapy, targeted therapy unfortunately not success cancers. Therefore, predictive have lagged behind identification tumours. Emerging research from new trials is cause guarded optimism may shift conceptualisation testing

Language: Английский

Citations

7
Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma DOI Open Access
Fábio França Vieira e Silva, Marina Di Domenico, Vito Carlo Alberto Caponio

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(1), P. 612 - 612

Published: Jan. 3, 2024

The O-6-methylguanine-DNA methyltransferase (MGMT) gene is a critical guardian of genomic integrity. MGMT methylation in diffuse gliomas serves as an important determinant patients' prognostic outcomes, more specifically glioblastomas (GBMs). In GBMs, the absence methylation, known promoter unmethylation, often translates into challenging clinical scenario, tending to present resistance chemotherapy and worse prognosis. A pyrosequencing (PSQ) technique was used analyze status at different cut-offs (5%, 9%, 11%) sample 78 patients diagnosed with IDH-wildtype grade 4 GBM. retrospective analysis provided collect clinicopathological data. statistical establish association between treatment response (TR) disease-specific survival (DSS). methylated experienced progressive disease rates 84.6%, 80%, 78.4% respective 5%, 11%. number considerably higher when considering unmethylated patients, all (100%), regardless cut-off, presented disease. Regarding (DSS), Hazard Ratio (HR) HR = 0.74 (0.45-1.24; p 0.251); 0.82 (0.51-1.33; 0.425); 0.79 (0.49-1.29; 0.350), respectively. Our study concludes that there unmethylation TR DSS. 9% cut-off demonstrated greater potential for patient function time, which may shed light on future need standardization positivity parameters PSQ.

Language: Английский

Citations

2
Patterns of T2-FLAIR discordance across a cohort of adult-type diffuse gliomas and deviations from the classic T2-FLAIR mismatch sign DOI
Prateek Malik, Radwa K. Soliman, Yingming Amy Chen

et al.

Neuroradiology, Journal Year: 2024, Volume and Issue: 66(4), P. 521 - 530

Published: Feb. 13, 2024

Language: Английский

Citations

2
Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance DOI

M.M. Lee,

Philipp Karschnia, Yae Won Park

et al.

Journal of Neuro-Oncology, Journal Year: 2024, Volume and Issue: 169(3), P. 531 - 541

Published: Aug. 8, 2024

Language: Английский

Citations

2
Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes DOI Creative Commons

Meetakshi Gupta,

Mustafa Anjari,

Sebastian Brandner

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(4), P. 901 - 901

Published: April 18, 2024

Isocitrate Dehydrogenase 1/2 (IDH 1/2)-wildtype (WT) astrocytomas constitute a heterogeneous group of tumors and have undergone series diagnostic reclassifications over time. This study aimed to investigate molecular markers, clinical, imaging, treatment factors predictive outcomes in WHO grade 2/3 IDH-WT ('early glioblastoma').

Language: Английский

Citations

1
MEX3A is a new diagnostic, independent prognostic biomarker and a promising therapeutic target in gliomas DOI Creative Commons
Francesca Bufalieri, Daniele Armocida, Antonino Cucinotta

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: May 13, 2024

Abstract Gliomas are the most common malignant brain tumors with a dismal prognosis. Despite progress in defining molecular features, no therapies targeting known biomarkers significantly increase survival rate of glioma patients. Recently, it has been demonstrated that high expression Muscle Excess 3A (MEX3A) gliomas correlates poor overall (OS), yet its clinical significance remains largely unknown. In this study, we assessed correlation between MEX3A and characteristics cohort 71 patients, determining diagnostic prognostic value exploring potential as an innovative therapeutic target. Our analysis revealed elevated associates more severe clinicopathological features Furthermore, exhibits accuracy OS progression free survival. Multivariate COX regression also identified independent factor for OS. Notably, genetic depletion inhibits primary human cells growth both in vitro vivo. finding emphasizes connection aspects indicating represents new biomarker, well promising

Language: Английский

Citations

0